Trevi Therapeutics (TRVI) said Monday a phase 2a trial of its investigational drug Haduvio met the primary endpoint of a statistically significant reduction in 24-hour cough frequency in patients with refractory chronic cough.
The company said Haduvio, or oral nalbuphine ER, achieved a reduction in 24-hour cough count of 67% from baseline and 57% on a placebo-adjusted basis at day 21.
Trevi said it plans to discuss the next steps with the US Food and Drug Administration and expects to initiate the next study after receiving the regulator's feedback.
Shares of the company rose more than 32% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。